Guignabert et al. also demonstrated that increased serum levels of Activin A and FSTL3 predict death or lung transplantation in both a discovery cohort and an independent external PAH cohort, highlighting their potential as prognostic biomarkers in PAH [63]. The gene discussed is FSTL3; the disease is pulmonary arterial hypertension.